{"pmid":32405989,"title":"Cardiovascular disease in the literature: A selection of recent original research papers.","text":["Cardiovascular disease in the literature: A selection of recent original research papers.","J Nucl Cardiol","AlJaroudi, Wael A","Hage, Fadi G","32405989"],"journal":"J Nucl Cardiol","authors":["AlJaroudi, Wael A","Hage, Fadi G"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405989","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s12350-020-02153-w","keywords":["cardiovascular disease","covid-19","epidemiology","myocardial ischemia","myocarditis","troponin"],"topics":["General Info"],"weight":1,"_version_":1666802845640294400,"score":9.490897,"similar":[{"pmid":32317203,"pmcid":"PMC7165109","title":"Cardiovascular complications in COVID-19.","text":["Cardiovascular complications in COVID-19.","BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19.","Am J Emerg Med","Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael","32317203"],"abstract":["BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19."],"journal":"Am J Emerg Med","authors":["Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317203","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajem.2020.04.048","keywords":["acute myocardial infarction","covid-19","cardiovascular","dysrhythmia","heart failure","infectious disease","myocarditis","troponin"],"topics":["Treatment"],"weight":1,"_version_":1666138493618749441,"score":86.92043},{"pmid":32315733,"pmcid":"PMC7166030","title":"Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms.","text":["Elevated Troponin in Patients With Coronavirus Disease 2019: Possible Mechanisms.","Coronavirus disease 2019 (COVID-19) is a pandemic that has affected more than 1.8 million people worldwide, overwhelmed health care systems owing to the high proportion of critical presentations, and resulted in more than 100,000 deaths. Since the first data analyses in China, elevated cardiac troponin has been noted in a substantial proportion of patients, implicating myocardial injury as a possible pathogenic mechanism contributing to severe illness and mortality. Accordingly, high troponin levels are associated with increased mortality in patients with COVID-19. This brief review explores the available evidence regarding the association between COVID-19 and myocardial injury.","J Card Fail","Tersalvi, Gregorio","Vicenzi, Marco","Calabretta, Davide","Biasco, Luigi","Pedrazzini, Giovanni","Winterton, Dario","32315733"],"abstract":["Coronavirus disease 2019 (COVID-19) is a pandemic that has affected more than 1.8 million people worldwide, overwhelmed health care systems owing to the high proportion of critical presentations, and resulted in more than 100,000 deaths. Since the first data analyses in China, elevated cardiac troponin has been noted in a substantial proportion of patients, implicating myocardial injury as a possible pathogenic mechanism contributing to severe illness and mortality. Accordingly, high troponin levels are associated with increased mortality in patients with COVID-19. This brief review explores the available evidence regarding the association between COVID-19 and myocardial injury."],"journal":"J Card Fail","authors":["Tersalvi, Gregorio","Vicenzi, Marco","Calabretta, Davide","Biasco, Luigi","Pedrazzini, Giovanni","Winterton, Dario"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315733","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cardfail.2020.04.009","keywords":["covid-19","coronavirus","myocardial injury","myocarditis","sars","troponin"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138493445734400,"score":74.20938},{"pmid":32442939,"title":"[Cardiovascular disease in times of COVID-19].","text":["[Cardiovascular disease in times of COVID-19].","There are increasing reports of a drastic drop in consultations and cardiovascular procedures (including urgencies and emergencies) in regions affected by the COVID-19 pandemic, with a consequent marked increase in total mortality that is not fully explained by COVID-19. Cardiovascular disease leads the ranking in deaths in adults in Argentina with 280 deaths per day, and in recent decades we have reduced its mortality by 20-30% through various evidence-based interventions. Herein we conducted predictive analyses to understand what could be the consequences of a worse implementation of those interventions. We estimate that less control of cardiovascular risk factors from April to October 2020 could cause up to 10 500 new preventable cases of cardiovascular disease. In terms of myocardial infarction, a drop from 40% to 60% of the reperfusion treatment could increase mortality by 3% to 5%. A marginal 10% to 15% increase in relative risk of cardiovascular death would be equivalent to an excess of 6000 to 9000 preventable deaths. In conclusion, given the high prevalence and fatality of cardiovascular disease, even a small negative impact on the efficacy of its care will translate into large numbers of people affected in Argentina. It is necessary to inform the authorities and educate the public so cardiovascular diseases and their risk factors remain a health priority, as long as resources exist and minimizing the risk of contagion and spread of the virus.","Medicina (B Aires)","Lamelas, Pablo","Botto, Fernando","Pedernera, Gustavo","Alves De Lima, Alberto","Costabel, Juan Pablo","Belardi, Jorge","32442939"],"abstract":["There are increasing reports of a drastic drop in consultations and cardiovascular procedures (including urgencies and emergencies) in regions affected by the COVID-19 pandemic, with a consequent marked increase in total mortality that is not fully explained by COVID-19. Cardiovascular disease leads the ranking in deaths in adults in Argentina with 280 deaths per day, and in recent decades we have reduced its mortality by 20-30% through various evidence-based interventions. Herein we conducted predictive analyses to understand what could be the consequences of a worse implementation of those interventions. We estimate that less control of cardiovascular risk factors from April to October 2020 could cause up to 10 500 new preventable cases of cardiovascular disease. In terms of myocardial infarction, a drop from 40% to 60% of the reperfusion treatment could increase mortality by 3% to 5%. A marginal 10% to 15% increase in relative risk of cardiovascular death would be equivalent to an excess of 6000 to 9000 preventable deaths. In conclusion, given the high prevalence and fatality of cardiovascular disease, even a small negative impact on the efficacy of its care will translate into large numbers of people affected in Argentina. It is necessary to inform the authorities and educate the public so cardiovascular diseases and their risk factors remain a health priority, as long as resources exist and minimizing the risk of contagion and spread of the virus."],"journal":"Medicina (B Aires)","authors":["Lamelas, Pablo","Botto, Fernando","Pedernera, Gustavo","Alves De Lima, Alberto","Costabel, Juan Pablo","Belardi, Jorge"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442939","source":"PubMed","week":"202021|May 18 - May 24","keywords":["covid-19","cardiovascular disease","epidemiology","myocardial infarction"],"locations":["Argentina","Argentina"],"countries":["Argentina"],"countries_codes":["ARG|Argentina"],"topics":["Prevention"],"weight":1,"_version_":1667523504868687873,"score":57.255848},{"pmid":32360126,"title":"Myocardial injury and COVID-19: Possible mechanisms.","text":["Myocardial injury and COVID-19: Possible mechanisms.","Coronavirus Disease 2019 (COVID-19) has quickly progressed to a global health emergency. Respiratory illness is the major cause of morbidity and mortality in these patients with the disease spectrum ranging from asymptomatic subclinical infection, to severe pneumonia progressing to acute respiratory distress syndrome. There is growing evidence describing pathophysiological resemblance of SARS-CoV-2 infection with other coronavirus infections such as Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus (MERS-CoV). Angiotensin Converting Enzyme-2 receptors play a pivotal role in the pathogenesis of the virus. Disruption of this receptor leads to cardiomyopathy, cardiac dysfunction, and heart failure. Patients with cardiovascular disease are more likely to be infected with SARS-CoV-2 and they are more likely to develop severe symptoms. Hypertension, arrhythmia, cardiomyopathy and coronary heart disease are amongst major cardiovascular disease comorbidities seen in severe cases of COVID-19. There is growing literature exploring cardiac involvement in SARS-CoV-2. Myocardial injury is one of the important pathogenic features of COVID-19. As a surrogate for myocardial injury, multiple studies have shown increased cardiac biomarkers mainly cardiac troponins I and T in the infected patients especially those with severe disease. Myocarditis is depicted as another cause of morbidity amongst COVID-19 patients. The exact mechanisms of how SARS-CoV-2 can cause myocardial injury are not clearly understood. The proposed mechanisms of myocardial injury are direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia.","Life Sci","Babapoor-Farrokhran, Savalan","Gill, Deanna","Walker, Jackson","Rasekhi, Roozbeh Tarighati","Bozorgnia, Behnam","Amanullah, Aman","32360126"],"abstract":["Coronavirus Disease 2019 (COVID-19) has quickly progressed to a global health emergency. Respiratory illness is the major cause of morbidity and mortality in these patients with the disease spectrum ranging from asymptomatic subclinical infection, to severe pneumonia progressing to acute respiratory distress syndrome. There is growing evidence describing pathophysiological resemblance of SARS-CoV-2 infection with other coronavirus infections such as Severe Acute Respiratory Syndrome coronavirus and Middle East Respiratory Syndrome coronavirus (MERS-CoV). Angiotensin Converting Enzyme-2 receptors play a pivotal role in the pathogenesis of the virus. Disruption of this receptor leads to cardiomyopathy, cardiac dysfunction, and heart failure. Patients with cardiovascular disease are more likely to be infected with SARS-CoV-2 and they are more likely to develop severe symptoms. Hypertension, arrhythmia, cardiomyopathy and coronary heart disease are amongst major cardiovascular disease comorbidities seen in severe cases of COVID-19. There is growing literature exploring cardiac involvement in SARS-CoV-2. Myocardial injury is one of the important pathogenic features of COVID-19. As a surrogate for myocardial injury, multiple studies have shown increased cardiac biomarkers mainly cardiac troponins I and T in the infected patients especially those with severe disease. Myocarditis is depicted as another cause of morbidity amongst COVID-19 patients. The exact mechanisms of how SARS-CoV-2 can cause myocardial injury are not clearly understood. The proposed mechanisms of myocardial injury are direct damage to the cardiomyocytes, systemic inflammation, myocardial interstitial fibrosis, interferon mediated immune response, exaggerated cytokine response by Type 1 and 2 helper T cells, in addition to coronary plaque destabilization, and hypoxia."],"journal":"Life Sci","authors":["Babapoor-Farrokhran, Savalan","Gill, Deanna","Walker, Jackson","Rasekhi, Roozbeh Tarighati","Bozorgnia, Behnam","Amanullah, Aman"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360126","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.lfs.2020.117723","keywords":["cardiovascular disease","coronavirus disease 2019","mechanisms of myocardial injury","myocardial injury","myocarditis","severe acute respiratory syndrome coronavirus-2"],"topics":["Mechanism"],"weight":1,"_version_":1666138495507234818,"score":56.841118},{"pmid":32347144,"title":"Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors.","text":["Current perspectives on Coronavirus 2019 (COVID-19) and cardiovascular disease: A white paper by the JAHA editors.","Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020, making it the most lethal pandemic since the Spanish flu of 1918.(1, 2) COVID-19 may preferentially infect individuals with cardiovascular conditions, is more severe in subjects with cardiovascular comorbidities, may directly or indirectly affect the heart and may interact with cardiovascular medications.(3) In addition, the widespread effects of the pandemic on the global healthcare system affects the routine and emergency cardiac care for patients who are, may be, or are not infected with COVID-19.","J Am Heart Assoc","Gupta, Ajay K","Jneid, Hani","Addison, Daniel","Ardehali, Hossein","Boehme, Amelia K","Borgaonkar, Sanket","Boulestreau, Romain","Clerkin, Kevin","Delarche, Nicolas","DeVon, Holli A","Grumbach, Isabella M","Gutierrez, Jose","Jones, Daniel A","Kapil, Vikas","Maniero, Carmela","Mentias, Amgad","Miller, Pamela S","May Ng, Sher","Parekh, Jai D","Sanchez, Reynaldo H","Teodor Sawicki, Konrad","S J M Te Riele, Anneline","Ann Remme, Carol","London, Barry","32347144"],"abstract":["Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has infected more than 3.0 million people worldwide and killed more than 200,000 as of April 27, 2020, making it the most lethal pandemic since the Spanish flu of 1918.(1, 2) COVID-19 may preferentially infect individuals with cardiovascular conditions, is more severe in subjects with cardiovascular comorbidities, may directly or indirectly affect the heart and may interact with cardiovascular medications.(3) In addition, the widespread effects of the pandemic on the global healthcare system affects the routine and emergency cardiac care for patients who are, may be, or are not infected with COVID-19."],"journal":"J Am Heart Assoc","authors":["Gupta, Ajay K","Jneid, Hani","Addison, Daniel","Ardehali, Hossein","Boehme, Amelia K","Borgaonkar, Sanket","Boulestreau, Romain","Clerkin, Kevin","Delarche, Nicolas","DeVon, Holli A","Grumbach, Isabella M","Gutierrez, Jose","Jones, Daniel A","Kapil, Vikas","Maniero, Carmela","Mentias, Amgad","Miller, Pamela S","May Ng, Sher","Parekh, Jai D","Sanchez, Reynaldo H","Teodor Sawicki, Konrad","S J M Te Riele, Anneline","Ann Remme, Carol","London, Barry"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32347144","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1161/JAHA.120.017013","keywords":["covid-19","cardiovascular disease","coronavirus disease 2019","sars-cov-2","cardiovascular risk factors","management","treatment"],"locations":["Spanish"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494932615168,"score":56.565044}]}